دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
The Platinum Hall of Fame
doi : 10.1016/j.eururo.2023.10.006
Volume 84, Issue 6, December 2023, Pages e127-e137
Early Detection of Prostate Cancer in the European Union: Combining Forces with PRAISE-U
Hendrik Van Poppel a,b,*, Monique J. Roobol c , Arunah Chandran
doi : 10.1016/j.eururo.2023.08.002
Volume 84, Issue 6, December 2023, Pages 519-522
Social Media Interventions for Patients and Public: Opportunities and Challenges for the Urology Community
Nikita R. Bhatt a,*, Jeremy Yuen-Chun Teoh b , Esther Garcia Rojo c , Vineet Gauhar d , Claudia Mercader e , Vito Cucchiara f,g,h , Carla Bezuidenhout i , Eamonn Rogers j , Maria J. Ribal e , Gianluca Giannarini k , on behalf of the European Association of Urology Guidelines Office Dissemination Committee and the European Association of Urology Patient Office
doi : 10.1016/j.eururo.2023.08.003
Volume 84, Issue 6, December 2023, Pages 523-526
Uncovering the Changing Treatment Landscape for Low-risk Prostate Cancer in the USA from 2010 to 2020: Insights from the National Cancer Data Base
Edoardo Beatrici a,b,f , Muhieddine Labban a , Benjamin V. Stone a , Dejan K. Filipas a,c , Leonardo O. Reis d,e , Giovanni Lughezzani b,f , Nicolo` M. Buffi b,f , Adam S. Kibel a , Alexander P. Cole a , Quoc-Dien Trinh a,*
doi : 10.1016/j.eururo.2023.09.002
Volume 84, Issue 6, December 2023, Pages 527-530
Clinical and Genomic Differences Between Advanced Molecular Imaging-detected and Conventional Imaging-detected Metachronous Oligometastatic Castration-sensitive Prostate Cancer
doi : 10.1016/j.eururo.2023.04.025
Volume 84, Issue 6, December 2023, Pages 531-535
Phase 2 Trial of Atezolizumab in Bacillus Calmette-Guérin–unresponsive High-risk Non–muscle-invasive Bladder Cancer: SWOG S1605
Peter C. Black a,*, Catherine M. Tangen b , Parminder Singh c , David J. McConkey d , M. Scott Lucia e , William T. Lowrance f , Vadim S. Koshkin g , Kelly L. Stratton h , Trinity J. Bivalacqua i , Wassim Kassouf j , Sima P. Porten g , Rick Bangs k , Melissa Plets b , Ian M. Thompson Jr l , Seth P. Lerner
doi : 10.1016/j.eururo.2023.08.004
Volume 84, Issue 6, December 2023, Pages 536-544
SWOG S1605: Moving Beyond Systemic Immune Checkpoint Inhibitor Monotherapy in Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer
Girish S. Kulkarni *, Marian S. Wettstein
doi : 10.1016/j.eururo.2023.09.013
Volume 84, Issue 6, December 2023, Pages 545-546
Primary Whole-gland Ablation for the Treatment of Clinically Localized Prostate Cancer: A Focal Therapy Society Best Practice Statement
Sriram Deivasigamani a,y, Srinath Kotamarti a,y, Ardeshir R. Rastinehad b , Rafael Sanchez Salas c , J.J.M.C.H. de la Rosette d , Herbert Lepor e , Peter Pinto f , Hashim U. Ahmed g , Inderbir Gill h , Laurence Klotz i , Samir S. Taneja e , Mark Emberton j , Nathan Lawrentschuk k , James Wysock e , John F. Feller l , Sebastien Crouzet m , Praveen Kumar M. n , Denis Seguier a,o , Eric S. Adams a , Zoe Michael a , Andre Abreu h , Kae Jack Tay p , John F. Ward q , Katsuto Shinohara r , Aaron E. Katz e , Arnauld Villers o , Joseph L. Chin s , Phillip D. Stricker t , Eduard Baco u , Petr Macek v , Ardalan E. Ahmad w , Peter K.F. Chiu x , E. David Crawford y , Craig G. Rogers z , Jurgen J. Futterer aa , Soroush Rais-Bahrami bb , Cary N. Robertson a , Boris Hadaschik cc , Giancarlo Marra dd , Massimo Valerio ee , Kian Tai Chong ff , Veeru Kasivisvanathan j , Wei Phin Tan e , Derek Lomas gg , Jochen Walz hh , Gustavo Cardoso Guimaraes ii , Nikos I. Mertziotis jj , Ezequiel Becher kk , Antonio Finelli i , Ali Kasraeian ll , Amir H. Lebastchi h , Anup Vora mm , Mark A. Rosen nn , Baris Bakir oo , Rohit Arcot a,pp , Samuel Yee x , Christopher Netsch qq , Xiaosong Meng rr , Theo M. de Reijke ss , Yu Guang Tan p , Stefano Regusci tt , Tavya G.R. Benjamin b , Ruben Olivares uu , Mohamed Noureldin vv , Fernando J. Bianco ww , Arjun Sivaraman xx , Fernando J. Kim yy , Robert W. Given zz , Shawn Dason aaa , Tyler J. Sheetz aaa , Sunao Shoji bbb , Ariel Schulman ccc , Peter Royce ddd , Taimur T. Shah
doi : 10.1016/j.eururo.2023.06.013
Volume 84, Issue 6, December 2023, Pages 547-560
Totally Intracorporeal Robot-assisted Unilateral or Bilateral Ileal Ureter Replacement for the Treatment of Ureteral Strictures: Technique and Outcomes from a Single Center
Kunlin Yang a,b,c,y, Xiang Wang a,b,c,y, Chunru Xu a,b,c,y, Zhihua Li a,b,c,y, Guanpen Han a,b,c , Shubo Fan a,b,c , Silu Chen a,b,c , Xinfei Li a,b,c , Hongjian Zhu d , Liqun Zhou a,b,c,*, Xuesong Li
doi : 10.1016/j.eururo.2023.04.022
Volume 84, Issue 6, December 2023, Pages 561-570
Nivolumab Switch Maintenance Therapy After Tyrosine Kinase Inhibitor Induction in Metastatic Renal Cell Carcinoma: A Randomized Clinical Trial by the Interdisciplinary Working Group on Renal Tumors of the German Cancer Society (NIVOSWITCH; AIO-NZK-0116ass)
Viktor Gru¨nwald a,*, Philipp Ivanyi b , Stefanie Zscha¨bitz c , Manfred Wirth d , Peter Staib e , Martin Schostak f , Philip Dargatz g , Lothar Mu¨ller h , Michael Metz i , Lothar Bergmann j , Thomas Steiner k , Martin Welslau l , Anja Lorch m,n , Reza Rafiyan o , Eva Hellmis p , Cristopher Darr q , Philipp Schu¨tt r , Johannes Meiler s , Thomas Kretz t , Wolfgang Loidl u , Anne Flo¨rcken v , Martin Ma¨nz w , Axel Hinke x , Arndt Hartmann y , Carsten Gru¨llich
doi : 10.1016/j.eururo.2023.09.004
Volume 84, Issue 6, December 2023, Pages 571-578
Impact of Relugolix Versus Leuprolide on the Quality of Life of Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study
Bertrand Tombal a,*, Sean Collins b , Alicia K. Morgans c , Elke Hunsche d , Bruce Brown e , Emily Zhu e , Alberto Bossi f , Neal Shore
doi : 10.1016/j.eururo.2023.09.007
Volume 84, Issue 6, December 2023, Pages 579-587
Presurgical 68Ga-PSMA-11 Positron Emission Tomography for Biochemical Recurrence Risk Assessment: A Follow-up Analysis of a Multicenter Prospective Phase 3 Imaging Trial
Lo?¨c Dja?¨leb a,*, Wesley R. Armstrong a,b , Daniel Thompson c , Andrei Gafita a , Andrea Farolfi a,d , Abhejit Rajagopal c , Tristan R. Grogan e , Kathleen Nguyen a , Matthias R. Benz a,f , Masatoshi Hotta a , Francesco Barbato g , Francesco Ceci h,i , Sarah M. Schwarzenbo¨ck j , Marcus Unterrainer k , Helle D. Zacho l , Roxanna Juarez c , Matthew Cooperberg m , Peter Carroll m,n , Samuel Washington m , Robert E. Reiter o,p , Matthias Eiber g , Ken Herrmann q,r , Wolfgang P. Fendler q,r , Johannes Czernin a,o , Thomas A. Hope c,n,y, Jeremie Calais
doi : 10.1016/j.eururo.2023.06.022
Volume 84, Issue 6, December 2023, Pages 588-596
Re: Germline Variants Associated with Toxicity to Immune Checkpoint Blockade
James O. Jones a,* Thomas J. Mitchell b Grant D. Stewart
doi : 10.1016/j.eururo.2023.03.008
Volume 84, Issue 6, December 2023, Page 597
Re: Real-time Changes in Brain Activity During Tibial Nerve Stimulation for Overactive Bladder: Evidence from Functional Near-infrared Spectroscopy Hype Scanning
doi : 10.1016/j.eururo.2023.06.032
Volume 84, Issue 6, December 2023, Page 598
Re: Sexual Behavior Shapes Male Genitourinary Microbiome Composition
Lorenz Leitner * Shawna McCallin
doi : 10.1016/j.eururo.2023.06.028
Volume 84, Issue 6, December 2023, Pages 598-599
Re: MRI-Detectability of Clinically Significant Prostate Cancer Relates to Oncologic Outcomes After Prostatectomy
Laurence Klotz
doi : 10.1016/j.eururo.2023.08.022
Volume 84, Issue 6, December 2023, Pages 599-600
Re: Dose-escalated Radiotherapy Alone or in Combination with Short-term Androgen Deprivation for Intermediate-risk Prostate Cancer: Results of a Phase III Multi-institutional Trial
Angela Y. Jia a,* Amar U. Kishan b Daniel E. Spratt
doi : 10.1016/j.eururo.2023.06.030
Volume 84, Issue 6, December 2023, Pages 600-601
Re: Radical Cystectomy Versus Trimodality Therapy for Muscle-invasive Bladder Cancer: A Multi-institutional Propensity Score Matched and Weighted Analysis
Antonio Cigliola a,* Chiara Mercinelli a Damiano Patanè a Daniele Raggi a Andrea Necchi
doi : 10.1016/j.eururo.2023.06.026
Volume 84, Issue 6, December 2023, Pages 602-603
A Pilot Study on Hyperthermic Intraperitoneal Chemotherapy after Radical or Partial Cystectomy with Pelvic Lymph Node Dissection for High-risk Muscle-invasive Bladder Cancer
Leonardo D. Borregales a , Siv Venkat a , Lina Posada Calderon a , Patrick Lewicki a , Thomas Flynn a , Bishoy M. Faltas b,c,d,e , Ana M. Molina b , David M. Golombos f , Padraic O’Malley g , Douglas S. Scherr
doi : 10.1016/j.eururo.2023.06.005
Volume 84, Issue 6, December 2023, Pages 604-606
Re: David-Dan Nguyen, Liam Murad, Anne Xuan-Lan Nguyen, et al. Industry Payments to American Editorial Board Members of Major Urology Journals. Eur Urol. 2023;84:442–43.
Anju Murayama
doi : 10.1016/j.eururo.2023.07.022
Volume 84, Issue 6, December 2023, Pages e138-e139
Reply to Anju Murayama’s Letter to the Editor re: David-Dan Nguyen, Liam Murad, Anne Xuan-Lan Nguyen, et al. Industry Payments to American Editorial Board Members of Major Urology Journals. Eur Urol. Eur Urol. 2023;84:442–43
David-Dan Nguyen a,y Anna-Lisa V. Nguyen b,y Liam Murad c Muhieddine Labban d Quoc-Dien Trinh d Christopher J.D. Wallis a,e Naeem Bhojani f,*
doi : 10.1016/j.eururo.2023.09.006
Volume 84, Issue 6, December 2023, Pages e140-e141
Re: Stavros Gravas, Mauro Gacci, Christian Gratzke, et al. Summary Paper on the 2023 European Association of Urology Guidelines on the Management of Non-neurogenic Male Lower Urinary Tract Symptoms. Eur Urol. 2023;84:207–22
Francesco Montorsi a,b Paolo Capogrosso c,d,* Federico Deh? c,d Andrea Salonia
doi : 10.1016/j.eururo.2023.08.017
Volume 84, Issue 6, December 2023, Page e142
Re: Matthew S. Ernst, Vishal Navani, J. Connor Wells, et al. Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma. Eur Urol 2023;84:109–16
Jonas Saal a,b,c Viktor Grünwald d Niklas Klümper
doi : 10.1016/j.eururo.2023.08.015
Volume 84, Issue 6, December 2023, Pages e143-e144
Re: Petros Grivas, Se Hoon Park, Eric Voog, et al. Avelumab First-line Maintenance Therapy for Advanced Urothelial Carcinoma: Comprehensive Clinical Subgroup Analyses from the JAVELIN Bladder 100 Phase 3 Trial. Eur Urol 2023;84:95–108
Yao-Ning Feng a,b,* Guang-Yu Xie a,b Li Xiao
doi : 10.1016/j.eururo.2023.07.021
Volume 84, Issue 6, December 2023, Page e145
Re: Jean-Nicolas Cornu, Paul Zantek, Glyn Burtt, et al. Minimally Invasive Treatments for Benign Prostatic Obstruction: A Systematic Review and Network Meta-analysis. Eur Urol 2023;83:534–47
Paolo Capogrosso a,b,* Federico Deh? a,b Andrea Salonia c,d Alberto Briganti c,d Francesco Montorsi
doi : 10.1016/j.eururo.2023.07.018
Volume 84, Issue 6, December 2023, Page e146
Reply to Palle Osther’s Words of Wisdom re: Inhibition of Sodium-Glucose Cotransporter 2 Suppresses Renal Stone Formation. Eur Urol. 2023;84:243–44
Go Anan a,b,* Takuo Hirose c,d Daisuke Kikuchi
doi : 10.1016/j.eururo.2023.06.019
Volume 84, Issue 6, December 2023, Pages e147-e148
Re: Elie Kaplan-Marans, Tenny R. Zhang, Jim C. Hu. Differing Recommendations on Prostate Biopsy Approach to Minimize Infections: An Examination of the European Association of Urology and American Urological Association Guidelines. Eur Urol. 2023;84:445–46
Fabian Falkenbach a Francesco Sanguedolce b Lars Bud?us a,*
doi : 10.1016/j.eururo.2023.08.031
Volume 84, Issue 6, December 2023, Pages e149-e150
Reply to Fabian Falkenbach, Francesco Sanguedolce, and Lars Budäus’s Letter to the Editor re: Elie Kaplan-Marans, Tenny R. Zhang, Jim C. Hu. Differing Recommendations on Prostate Biopsy Approach to Minimize Infections: An Examination of the European Association of Urology and American Urological Association Guidelines. Eur Urol. 2023;84:445–46
Elie Kaplan-Marans a,* Tenny R. Zhang b Jim C. Hu b,c
doi : 10.1016/j.eururo.2023.08.029
Volume 84, Issue 6, December 2023, Page e151
Re: Gyrithe Lynghøj Pedersen, Marie Schmidt Erikson, Karin Mogensen, Susanne Rosthøj, Gregers Gautier Hermann. Outpatient Photodynamic Diagnosis-guided Laser Destruction of Bladder Tumors Is as Good as Conventional Inpatient Photodynamic Diagnosis-guided Transurethral Tumor Resection in Patients with Recurrent Intermediate-risk Low-grade Ta Bladder Tumors. A Prospective Randomized Noninferiority Clinical Trial. Eur Urol 2023;83:125–30
Deng-Xiong Li y De-Chao Feng y Shi Deng
doi : 10.1016/j.eururo.2023.06.029
Volume 84, Issue 6, December 2023, Pages e152-e153
Reply to Deng-Xiong Li, De-Chao Feng, and Shi Deng’s Letter to the Editor re: Gyrithe Lynghøj Pedersen, Marie Schmidt Erikson, Karin Mogensen, Susanne Rosthøj, Gregers Gautier Hermann. Outpatient Photodynamic Diagnosis-guided Laser Destruction of Bladder Tumors Is as Good as Conventional Inpatient Photodynamic Diagnosis-guided Transurethral Tumor Resection in Patients with Recurrent Intermediate-risk Low-grade Ta Bladder Tumors. A Prospective Randomized Noninferiority Clinical Trial. Eur Urol 2023;83:125–30
Gyrithe Lyngh?j Pedersen a,* Karin Mogensen a Susanne Rosth?j b Gregers Gautier Hermann
doi : 10.1016/j.eururo.2023.07.002
Volume 84, Issue 6, December 2023, Page e154
Congress Calendar
doi : 10.1016/j.eururo.2023.10.008
Volume 84, Issue 6, December 2023, Pages e155-e156
Acknowledgement to Reviewers
doi : 10.1016/j.eururo.2023.10.007
Volume 84, Issue 6, December 2023, Pages e157-e159
In memoriam Urs Studer (1944–2023)
doi : 10.1016/j.eururo.2023.10.009
Volume 84, Issue 6, December 2023, Pages 607-608
